154 related articles for article (PubMed ID: 20230187)
1. GAD-alum (Diamyd)--a new concept for preservation of residual insulin secretion.
Ludvigsson J
Expert Opin Biol Ther; 2010 May; 10(5):787-99. PubMed ID: 20230187
[TBL] [Abstract][Full Text] [Related]
2. GAD-alum immunotherapy in Type 1 diabetes mellitus.
Morales AE; Thrailkill KM
Immunotherapy; 2011 Mar; 3(3):323-32. PubMed ID: 21395375
[TBL] [Abstract][Full Text] [Related]
3. Therapy with GAD in diabetes.
Ludvigsson J
Diabetes Metab Res Rev; 2009 May; 25(4):307-15. PubMed ID: 19267332
[TBL] [Abstract][Full Text] [Related]
4. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
[TBL] [Abstract][Full Text] [Related]
5. GAD65: a prospective vaccine for treating Type 1 diabetes?
Ludvigsson J
Expert Opin Biol Ther; 2017 Aug; 17(8):1033-1043. PubMed ID: 28480759
[TBL] [Abstract][Full Text] [Related]
6. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
[TBL] [Abstract][Full Text] [Related]
7. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
Ludvigsson J; Chéramy M; Axelsson S; Pihl M; Akerman L; Casas R;
Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
[TBL] [Abstract][Full Text] [Related]
8. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
Chéramy M; Skoglund C; Johansson I; Ludvigsson J; Hampe CS; Casas R
Clin Immunol; 2010 Oct; 137(1):31-40. PubMed ID: 20580618
[TBL] [Abstract][Full Text] [Related]
9. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Wherrett DK; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Herold KC; Marks JB; Monzavi R; Moran A; Orban T; Palmer JP; Raskin P; Rodriguez H; Schatz D; Wilson DM; Krischer JP; Skyler JS;
Lancet; 2011 Jul; 378(9788):319-27. PubMed ID: 21714999
[TBL] [Abstract][Full Text] [Related]
10. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
Ludvigsson J; Krisky D; Casas R; Battelino T; Castaño L; Greening J; Kordonouri O; Otonkoski T; Pozzilli P; Robert JJ; Veeze HJ; Palmer J; Samuelsson U; Elding Larsson H; Åman J; Kärdell G; Neiderud Helsingborg J; Lundström G; Albinsson E; Carlsson A; Nordvall M; Fors H; Arvidsson CG; Edvardson S; Hanås R; Larsson K; Rathsman B; Forsgren H; Desaix H; Forsander G; Nilsson NÖ; Åkesson CG; Keskinen P; Veijola R; Talvitie T; Raile K; Kapellen T; Burger W; Neu A; Engelsberger I; Heidtmann B; Bechtold S; Leslie D; Chiarelli F; Cicognani A; Chiumello G; Cerutti F; Zuccotti GV; Gomez Gila A; Rica I; Barrio R; Clemente M; López Garcia MJ; Rodriguez M; Gonzalez I; Lopez JP; Oyarzabal M; Reeser HM; Nuboer R; Stouthart P; Bratina N; Bratanic N; de Kerdanet M; Weill J; Ser N; Barat P; Bertrand AM; Carel JC; Reynaud R; Coutant R; Baron S
N Engl J Med; 2012 Feb; 366(5):433-42. PubMed ID: 22296077
[TBL] [Abstract][Full Text] [Related]
11. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
Ludvigsson J; Hjorth M; Chéramy M; Axelsson S; Pihl M; Forsander G; Nilsson NÖ; Samuelsson BO; Wood T; Aman J; Ortqvist E; Casas R
Diabetologia; 2011 Mar; 54(3):634-40. PubMed ID: 21116604
[TBL] [Abstract][Full Text] [Related]
12. Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes.
Hinke SA
Curr Opin Mol Ther; 2008 Oct; 10(5):516-25. PubMed ID: 18830927
[TBL] [Abstract][Full Text] [Related]
13. 2011 Update: antigen-specific therapy in type 1 diabetes.
Michels AW; von Herrath M
Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):235-40. PubMed ID: 21844706
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies in the management of type I diabetes mellitus.
Ludvigsson J
Panminerva Med; 2012 Dec; 54(4):257-70. PubMed ID: 23123577
[TBL] [Abstract][Full Text] [Related]
15. Combined Etanercept, GAD-alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes.
Ludvigsson J; Routray I; Vigård T; Hanås R; Rathsman B; Carlsson A; Särnblad S; Albin AK; Arvidsson CG; Samuelsson U; Casas R
Diabetes Metab Res Rev; 2021 Oct; 37(7):e3440. PubMed ID: 33486892
[TBL] [Abstract][Full Text] [Related]
16. Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients.
Casas R; Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
Front Immunol; 2020; 11():564921. PubMed ID: 33162978
[TBL] [Abstract][Full Text] [Related]
17. Does immune-tolerance treatment with Alum-formulated GAD65 protect insulin-production in the pancreatic islet β cells?
Larsson HE; Lernmark A
Hum Vaccin; 2011 Jan; 7(1):45-9. PubMed ID: 21263221
[TBL] [Abstract][Full Text] [Related]
18. GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.
Skoglund C; Chéramy M; Casas R; Ludvigsson J; Hampe CS
Pediatr Diabetes; 2012 May; 13(3):244-50. PubMed ID: 21848927
[TBL] [Abstract][Full Text] [Related]
19. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
[TBL] [Abstract][Full Text] [Related]
20. Glutamic acid decarboxylase autoantibody-positivity post-partum is associated with impaired β-cell function in women with gestational diabetes mellitus.
Lundberg TP; Højlund K; Snogdal LS; Jensen DM
Diabet Med; 2015 Feb; 32(2):198-205. PubMed ID: 25345799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
